Methylation of MGMT Is Associated with Poor Prognosis in Patients with Stage III Duodenal Adenocarcinoma.

Tao FuAnup SharmabFei XieYanliang LiuKai LiWeiwei WanStephen B BaylinChristopher L WolfgangNita Ahuja

Published in: PloS one (2016)

Our results demonstrate MGMT methylation is a reliable and independent prognostic factor in DAs. Methylation of MGMT is associated with poor prognosis in patients with stage III DAs.

Keyphrases

poor prognosis
prognostic factors
long non coding rna
genome wide
dna methylation
disease activity
squamous cell carcinoma
rheumatoid arthritis
systemic lupus erythematosus
radiation therapy